These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 26733616

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
    Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C.
    N Engl J Med; 2012 Oct 11; 367(15):1417-27. PubMed ID: 23050525
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E.
    Carcinogenesis; 2019 Nov 25; 40(11):1320-1331. PubMed ID: 31169881
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.
    J Thorac Oncol; 2013 Jul 25; 8(7):947-51. PubMed ID: 23777840
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.
    Clin Cancer Res; 2007 May 15; 13(10):2928-35. PubMed ID: 17504993
    [Abstract] [Full Text] [Related]

  • 14. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2014 Dec 15; 34(12):7425-9. PubMed ID: 25503183
    [Abstract] [Full Text] [Related]

  • 15. ATG5 as biomarker for early detection of malignant mesothelioma.
    Tomasetti M, Monaco F, Strogovets O, Volpini L, Valentino M, Amati M, Neuzil J, Santarelli L.
    BMC Res Notes; 2023 Apr 24; 16(1):61. PubMed ID: 37095543
    [Abstract] [Full Text] [Related]

  • 16. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.
    Lung Cancer; 2013 Dec 24; 82(3):491-8. PubMed ID: 24161718
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.
    Thorax; 2014 Oct 24; 69(10):895-902. PubMed ID: 25037982
    [Abstract] [Full Text] [Related]

  • 19. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.
    Clin Chem Lab Med; 2011 Oct 24; 49(10):1721-6. PubMed ID: 21692685
    [Abstract] [Full Text] [Related]

  • 20. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.
    Lung Cancer; 2011 Oct 24; 74(1):55-60. PubMed ID: 21397972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.